Exclusive Summary

• - Patents expired globally; standard 100/200 mg strengths enable fast registration and scalable supply.
• - Targets IBS and functional GI disorders; Rome IV prevalence ~4% equals >320 million patients worldwide with ongoing symptomatic treatment needs.
• - Approved in Canada; Health Canada (WHO-designated SRA) approval supports reliance pathways and rapid market entry for distribution deals.
• - Antispasmodics are commonly recommended for IBS symptom control in many guidelines; trimebutine is widely used outside the U.S. with favorable tolerability.
• - Generic pricing typically 50–70% below originator, well-suited for cash-pay and limited-reimbursement markets.